news-med.jpg

Laura Catalina

Recent Posts

Evotec expands CRISPR-based technology offering with licence from ERS genomics

Hamburg, Germany, 02 May 2018: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that it has expanded its CRISPR service offering with the addition of a licence from ERS Genomics Limited. With this licence, Evotec gains access to the leading technology for gene ...

Topics: Corporate, crispr, genomics, technology Read More

Evotec AG announces first nine-month 2017 results and corporate update

Strong operational and financial performance Expansion of leading external innovation platform through acquisition of aptuit Important milestone achievements and new ways of accelerating innovation Hamburg, Germany, 08 November 2017: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: ...

Topics: Corporate, Drug Discovery, Drug Development Read More

Evotec joins forces with Academic Leaders to accelerate Drug Discovery in kidney diseases and build “Neplex”

Collaboration aimed at developing novel “Nephron-on-a Chip” device to test drug candidates in human kidney: NEPLEX (“Nephron-on-a-Chip with Cellular and Extracellular Matrix Complexity”) Major step forward to the next generation Kidney Platform Hamburg, Germany, 06 November 2017: Evotec AG ...

Topics: Corporate, Drug Discovery, Drug Development Read More

Evotec AG to report first nine-month 2017 results on 08 November 2017

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) will report its financial results for the first nine months of 2017 on Wednesday, 08 November 2017. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The ...

Topics: Corporate Read More

New Research by Cyprotex on Transporter DDI Published in Pharmacology Research & Perspectives

New research by Cyprotex in the field of metformin drug-drug interactions has been published in Pharmacology Research & Perspectives. The publication assists in further understanding the mechanism behind clinically observed DDIs with the common co-medication, metformin. Read our blog and download ...

Topics: Corporate, Drug Discovery, Drug Development Read More

Evotec and Tesaro Enter Strategic Partnership To Discover Novel Immuno-Oncology Agents

Discovery and development of inhibitors against Tesaro's Immuno-Oncology target utilising Evotec's comprehensive discovery and development platform Hamburg, Germany, 26 October 2017: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and TESARO, Inc. (“TESARO”) today announced a ...

Topics: Corporate, Drug Discovery, Drug Development Read More

Evotec Achieves First Milestone In Neurodegeneration Alliance With Celgene

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its strategic alliance with Celgene has reached a first milestone triggering revenues of $ 5.0 m to Evotec, which are recognised in the third quarter of 2017. The milestone is due to the successful completion ...

Topics: Corporate, Drug Discovery, Drug Development, Partner Research Organization Read More

Most Read

Posts by Topic